News & Events

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

2026 ESMO丨全新一代KRAS G12C抑制剂:Divarasib以III期头对头全面获益,彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻

2026 ESMO丨全新一代KRAS G12C抑制剂:Divarasib以III期头对头全面获益,彰显KRAS G12C突变NSCLC后线治疗同类最佳潜力_腾讯新闻

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

New Standard-of-Care for KRAS G12C-Mutated Advanced NSCLC

How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC?

How Does Divarasib Compare With Other KRAS Inhibitors in NSCLC?

Dr Skoulidis on Emerging KRAS Inhibitors in NSCLC

Dr Skoulidis on Emerging KRAS Inhibitors in NSCLC

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

Sotorasib (Lumakras; AMG 510): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Lung and Colorectal Cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC